OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial introduction	244
Giant cell arteritis: update on pathogenesis and clinical implications	67
Current approach to muscle imaging in myositis	62
What's next in psoriatic arthritis therapy? A look at the pipeline	53
Epidemiology and outcomes of rheumatoid arthritis	50
Current views on lupus in children	49
Selective immunoglobulin E deficiency: an overlooked hypogammaglobulinemia and its association with rheumatoid arthritis	49
Urticarial vasculitis	47
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	39
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	35
Editorial introductions	35
Osteoporosis epidemiology using international cohorts	34
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden	34
Axial spondyloarthritis guidelines – aiming for maximum impact	30
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	25
A comprehensive review of systemic sclerosis–primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype	24
The gut microbiota in spondyloarthritis: an update	23
Comorbidities in idiopathic inflammatory myopathies: population-based evidence on risk subgroups and implications for delivery of care	22
Rheumatoid arthritis – the challenge of heterogeneity	21
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	21
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	20
Editorial introductions	19
Updates on translational and clinical research in systemic sclerosis	19
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	18
Editorial introductions	18

Editorial introductions	17
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	17
Editorial introduction	16
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	16
Pathogenesis of skin damage in lupus: recent advances and future directions	16
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	15
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	15
Defining and managing flares in axial spondyloarthritis	14
Health inequities in the rheumatic diseases of childhood	14
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	14
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	14
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	13
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	13
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	13
How common is vasculitis: what do population-based data tell us?	13
Epidemiology of myositis	13
AI am the future: artificial intelligence in pediatric rheumatology	12
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	12
New developments related to lung complications in pediatric rheumatic disease	12
Biomarker discovery in psoriatic disease	12
Editorial introductions	12
Diagnosis and management of primary heart involvement in systemic sclerosis	11
Advances in the diagnosis and treatment of Sjögren disease	11
Epidemiology of osteoarthritis: literature update 2022–2023	11
Environmental and occupational contributors to autoimmune, inflammatory, and musculoskeletal rheumatic disease: a review of emerging evidence and clinical implications	11
Exploring challenges in the management and treatment of inclusion body myositis	11
Management of postinfectious inflammatory arthritis	11
Editorial introduction	11
Investigating gout flares: beyond a definition	11
Emerging biologic therapies for systemic lupus erythematosus	11
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	10
Animal models in systemic sclerosis: an update	10
Heart involvement in systemic sclerosis: emerging concepts	10
Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications	10
Update on streptococcal-associated rheumatic disease	10
Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances	10
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	10
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	10
Vasculitis and the NLRP3 inflammasome	10
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	9
Revisiting the CD40-CD40L axis: from mechanistic insight to therapeutic renewal in autoimmune disease	9
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	9
Treatment of systemic vasculitis	9
Editorial introduction	9
The contribution of endothelial cells to tissue fibrosis	9
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	9
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	9
Current management of giant cell arteritis and its complications	9
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	9
What have we learned about systemic sclerosis from the EUSTAR database?	9

Biomarkers in juvenile idiopathic arthritis: towards precision diagnosis and personalized therapy?	9
Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis	8
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	8
Osteoarthritis gene therapy in 2022	7
What are mice teaching us about psoriatic arthritis?	7
Calcinosis in systemic sclerosis	7
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	7
Update on muscle imaging in myositis	7
New therapies in anti-MDA5 antibody-positive dermatomyositis	7
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	7
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	6
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	6
Editorial introductions	6
Go or no-go for treat-to-target in axial spondyloarthritis?	6
Epidemiology of systemic vasculitis	6
Recent advances in immunometabolism in rheumatic diseases	6
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	6
Contribution of keratinocytes to dermal fibrosis	6
Clinical endpoints in myositis: challenges and ways forward	6
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	6
Quo vadis reactive arthritis?	6
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	6
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	6
Updates in juvenile dermatomyositis: pathogenesis and therapy	5
Editorial introduction	5
Spatial transcriptomics: challenges and future directions in musculoskeletal diseases	5
Calcinosis in systemic sclerosis	5
Neuropsychiatric systemic lupus erythematosus – current and novel treatments	5
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	5
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	5
Should CAR-T cells be used as monotherapy?	5
Rethinking spondyloarthritis: beyond lumping and splitting	5
Omics studies in Behçet's disease	5
Management of patients with antiphospholipid antibodies or antiphospholipid syndrome during pregnancy	5
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	5
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
Renal disease in pediatric rheumatology	5
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	4
Editorial myositis and myopathies	4
Vaccination updates and special considerations for systemic lupus erythematosus patients	4
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	4
The impact of omics research on our understanding of osteoarthritis and future treatments	4
Editorial introduction	4
Advances in osteoarthritis imaging	4
Methods for objective assessment of skin involvement in systemic sclerosis	4
Regulatory T cells and systemic vasculitis	4
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	4
Disease modification in axial spondyloarthritis – still a controversy?	4
Drug therapy in juvenile spondyloarthritis	4
Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management	4
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	4
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	4
An update on topical therapies for psoriasis	3
Rheumatologic immune checkpoint inhibitor-related adverse events	3
Microbiome dynamics in rheumatic diseases	3
Human genetics of Whipple's disease	3
An update on inflammation in antiphospholipid syndrome	3
Novel therapies in juvenile idiopathic arthritis	3
New molecular targets in the treatment of rheumatoid arthritis	3
Pathophysiologic implications and therapeutic potentials of telocytes in multiorgan fibrosis	3
Harnessing artificial intelligence to advance insights in systemic sclerosis skin and lung disease	3
Updates in uricase therapy for gout	3
Understanding psoriatic disease at single-cell resolution: an update	3
Update on treatment responses and outcome measure development in chronic nonbacterial osteomyelitis	3
Gastrointestinal manifestations of systemic sclerosis: current approaches and emerging therapies	3
SGLT-2 inhibitors: new horizons for rheumatologists	3
Vasculitis associated with nonhematological malignancies	3